Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Telcon RF Pharmaceutical Inc. (200230:KRX), powered by AI.
Telcon RF Pharmaceutical Inc. is currently trading at ₩780. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Telcon RF Pharmaceutical Inc. on Alpha Lenz.
Telcon RF Pharmaceutical Inc.'s P/E ratio is -1.3.
“Telcon RF Pharmaceutical Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -28.1%.”
Ask for details →Telcon RF Pharmaceutical Inc. is a company operating in the pharmaceutical and health technology sectors. Its primary focus is on the research, development, and commercialization of pharmaceutical products that address a variety of health conditions. The company is known for integrating advanced RF technology into pharmaceutical solutions, aiming to enhance drug delivery and efficacy, which sets it apart in the industry. This innovation positions Telcon RF Pharmaceutical as a significant player in the pharmaceutical industry, where technology increasingly intersects with traditional healthcare models. By concentrating on both domestic and international markets, Telcon RF Pharmaceutical seeks to address a broad spectrum of healthcare needs, thus maintaining a diverse portfolio that is significant for healthcare providers and patients alike. As the company continues to expand its research capabilities and product offerings, it holds a crucial role in advancing healthcare solutions worldwide, contributing to improved patient outcomes and modern healthcare practices.
“Telcon RF Pharmaceutical Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -28.1%.”
Ask for details →Telcon RF Pharmaceutical Inc. (ticker: 200230) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 124 employees. Market cap is $53.4B.
The current price is ₩780 with a P/E ratio of -1.3x and P/B of 0.41x.
ROE is -28.11% and operating margin is -0.19%. Annual revenue is $37.9B.